Optic neuropathy after chimeric antigen receptor T-cell therapy

Optic neuropathy after chimeric antigen receptor T-cell therapy

Bibliographic Details
Main Authors:	Ching-Wen Huang, Cheng-Hong Tsai, Chao-Wen Lin
Format:	Article
Language:	English
Published:	Elsevier 2022-05-01
Series:	Journal of the Formosan Medical Association
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664621004927

Similar Items

Chimeric Antigen Receptor-T Cell Therapy
by: Jochen Buechner, et al.
Published: (2018-02-01)

Chimeric antigen receptor T cell therapies for multiple myeloma
by: Chao Wu, et al.
Published: (2019-11-01)

Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma
by: Kun Ma, et al.
Published: (2023-11-01)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
by: Bryanna Reinhardt, et al.
Published: (2023-02-01)

Chimeric Antigen Receptor T Cell Therapy in Hematology
by: Pınar Ataca, et al.
Published: (2015-11-01)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
by: Panpan Chen, et al.
Published: (2022-10-01)

Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
by: Zili Lin, et al.
Published: (2021-09-01)

Chimeric antigen receptor‐T cell therapies: The changing landscape
by: Salyka M. Sengsayadeth, et al.
Published: (2022-01-01)

Chimeric antigen receptor T-cell therapy for multiple myeloma
by: Zehua Wang, et al.
Published: (2022-12-01)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
by: Wenwen Wei, et al.
Published: (2022-11-01)

Chimeric antigen receptor T cell therapy for multiple myeloma
by: Kana Hasegawa, et al.
Published: (2019-06-01)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
by: David L Porter, Michael Kalos, Zhaohui Zheng, Bruce Levine, Carl June
Published: (2011-01-01)

Engineering chimeric antigen receptor T cells for solid tumour therapy
by: Longwei Liu, et al.
Published: (2022-12-01)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
by: Xiao Han, et al.
Published: (2019-11-01)

Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy
by: Baptiste Le Calvez, et al.
Published: (2022-05-01)

Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma—Recent Advances
by: Adrian Kowalczyk, et al.
Published: (2024-01-01)

New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy
by: Wan-Tai Wu, et al.
Published: (2021-02-01)

Role of bridging therapy during chimeric antigen receptor T cell therapy
by: Shakthi T. Bhaskar, et al.
Published: (2022-01-01)

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
by: Hua Li, et al.
Published: (2017-04-01)

Chimeric antigen receptor-T-cell therapy: China leading the way
by: Robert Peter Gale
Published: (2022-07-01)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
by: Long Li, et al.
Published: (2020-11-01)

Chimeric antigen receptor T-cell therapy in hematopoietic and nonhematopoietic malignancies
by: Faizan Ahmad
Published: (2020-01-01)

Fusarium rhinosinusitis post chimeric antigen receptor T-cell therapy
by: Supavit Chesdachai, et al.
Published: (2021-01-01)

Switching on the green light for chimeric antigen receptor T‐cell therapy
by: Sherly Mardiana, et al.
Published: (2019-01-01)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
by: Yanyu Pang, et al.
Published: (2018-05-01)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
by: Mengyi Du, et al.
Published: (2020-05-01)

Engineering better chimeric antigen receptor T cells
by: Hao Zhang, et al.
Published: (2020-12-01)

Universal chimeric antigen receptor T cell therapy — The future of cell therapy: A review providing clinical evidence
by: Wenxuan Sun, et al.
Published: (2022-01-01)

Intravascular clusters of T cells following chimeric antigen receptor T cell therapy
by: Naokazu Nakamura, et al.
Published: (2022-05-01)

Telemedicine in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T Cell Therapy
by: Arpita P. Gandhi, et al.
Published: (2023-08-01)

Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
by: Wenyujing Zhou, et al.
Published: (2022-01-01)

A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
by: Zili Lin, et al.
Published: (2021-09-01)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
by: Avirup Guha, et al.
Published: (2021-08-01)

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
by: Haobing Wang, et al.
Published: (2023-05-01)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
by: Kamila Polgárová, et al.
Published: (2022-05-01)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
by: Maria Giraudo, et al.
Published: (2024-03-01)

439 Cardiovascular safety of chimeric antigen receptor (CAR) T cell therapy
by: Norbert Frey, et al.
Published: (2023-11-01)

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
by: Ross E Staudt, et al.
Published: (2022-12-01)

Chimeric antigen receptor engineered natural killer cells for cancer therapy
by: Yalan Zhang, et al.
Published: (2023-08-01)

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
by: Amy J. Petty, et al.
Published: (2020-03-01)